VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Tumban, Ebenezer ^a   Peabody, Julianne ^a   Tyler, Mitchell ^a   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; COAT PROTEIN; EPITOPE; RECOMBINANT L2 COAT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENITAL TRACT INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; MS2 VIRUS; NONHUMAN; PAPILLOMAVIRUS INFECTION; SKIN INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; LEVIVIRUS; MICE; MICE, INBRED BALB C; MODELS, GENETIC; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; VACCINES, VIRUS-LIKE PARTICLE; VIRUSES;

HUMAN PAPILLOMAVIRUS; MIRIDAE; MUS;

EID: 84869830694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049751     Document Type: Article

References (36)

1. Castellsague X, Sanjose S, Aguado T, Louie K, Bruni L, et al. (2007) HPV and cervical cancer in the World 2007 Report. Vaccine 25 (Suppl 3):: C1-230.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
3. Burd EM, (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16: 1-17.
4. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199: 936-944.
5. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
6. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, et al. (2007) Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3: 109-115.
7. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255.
9. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
10. Peres J, (2011) For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst 103: 360-362.
11. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
12. Tumban E, Peabody J, Peabody DS, Chackerian B, (2011) A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 6: e23310.
13. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
14. Jagu S, Kwak K, Garcea RL, Roden RB, (2010) Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 28: 4478-4486.
15. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358: 266-272.
16. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
17. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, et al. (2005) Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337: 365-372.
18. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850-5855.
19. Christensen ND, Kreider JW, Kan NC, DiAngelo SL, (1991) The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181: 572-579.
20. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, et al. (2010) Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28: 4384-4393.
21. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, et al. (2008) Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 380: 252-263.
22. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, et al. (2010) Versatile virus-like particle carrier for epitope based vaccines. PLoS One 5: e9809.
23. Peabody DS, (1997) Subunit fusion confers tolerance to peptide insertions in a virus coat protein. Arch Biochem Biophys 347: 85-92.
24. Campos SK, Ozbun MA, (2009) Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One 4: e4463.
25. Kawana K, Yasugi T, Kanda T, Kino N, Oda K, et al. (2003) Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21: 4256-4260.
26. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180-12184.
27. Smith ML, Lindbo JA, Dillard-Telm S, Brosio PM, Lasnik AB, et al. (2006) Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348: 475-488.
28. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T, (2008) Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80: 841-846.
29. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, et al. (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25: 2001-2010.
30. Caldeira Jdo C, Peabody DS, (2011) Thermal stability of RNA phage virus-like particles displaying foreign peptides. J Nanobiotechnology 9: 22.
31. Chackerian B, Caldeira Jdo C, Peabody J, Peabody DS, (2011) Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. J Mol Biol 409: 225-237.
32. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
33. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT, (2005) Maturation of papillomavirus capsids. J Virol 79: 2839-2846.
34. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.
35. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
36. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81: 13927-13931.